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The co-existence of viruses and organisms for millions
of years has influenced the evolution of both. Various
viral strategies to enter a host and take over the control
of cells to produce virus progeny have developed.
Several antiviral (immune) responses have also been
developed. The apoptotic death program is a conserved
feature of eukaryotic cells. In multicellular organisms
the binding and engulfment of apoptotic material is
considered to be the end stage of the apoptotic process.
Because of its importance, it seems probable that
viruses have targeted this ancient removal system to
suppress immune responses and to establish or main-
tain infection. The possibility that the hepatitis B virus
has evolved such a mechanism, termed ‘viral apoptotic-
like mimicry’, is presented here.
In the past 15 years there has been a tremendous increase
in the understanding of the molecular biology of pro-
grammed cell death, especially apoptotic cell death. This
process is essential for development, morphogenesis and
tissue modelling but also has a key role in immune
homeostasis [1]. However, without an equally well
organized removal process, apoptosis loses its purpose.
Indeed, evidence is accumulating that the persistence
of apoptotic cells (APCEs) leads to (or contributes to)
inflammatory and autoimmune diseases, such as systemic
lupus erythematosus. Viruses have shaped the evolution of
organisms and vice versa. It is therefore not a surprise that
when new cellular and immune mechanisms are dis-
covered, viruses are found that have evolved to manipulate
these pathways to their own advantage [2,3]. The APCE
removal system is highly conserved, highly effective and
designed to prevent tissue damage, inflammation and the
development of (auto)immunity. Therefore, it is remark-
able that no virus that takes advantage of the machinery to
remove APCEs has yet been described.
The hepatitis B virus (HBV) is one of the most
successful human pathogens. Two billion of the six billion
people alive today show evidence of past or current
infection with this virus and ,350–400 million people
are persistently infected with HBV. Besides infectious
virions (Dane particles), HBV-infected hepatocytes pro-
duce non-infectious subviral particles [termed hepatitis B
surface antigen (HBsAg)]. HBsAg consists mainly of
spherical particles that can accumulate at 100 mg ml21
in the blood of HBV-infected patients and exceed infectious
virions in number by a factor of 100–10 000. HBsAg
particles contain viral-encoded membrane proteins (S, M
and L) and ,30% (by weight) of host-cell-derived lipids. A
possible role for HBsAg in the establishment and
maintenance of HBV persistence has been suggested [4].
It is thought that HBsAg maintains viral persistence by
absorbing the virus-neutralizing antibodies. It is further
hypothesized that HBsAg-derived peptides saturate MHC
molecules and prevent presentation of other viral-derived
peptides. HBsAg might also deplete CD4 and CD8 cells
by clonal exhaustion and cause cytotoxic T-lymphocyte
(CTL)-mediated depletion of T and B cells, which take up
HBsAg into the MHC class I processing pathway. However,
no experimental evidence to support these hypotheses has
been obtained [4]. Therefore, the reason for the existence,
or the possible advantage, of the production of HBsAg
remains elusive. It is, however, remarkable that during
acute and chronic infections a clear HBsAg-specific Th-cell
and humoral response is difficult to demonstrate, despite
the circulation of HBsAg [4]. Based on recent insights into
the mechanism of APCE removal, a hypothesis is pre-
sented, in which HBsAg acts like an apoptotic-cell mimic
and interacts with the ancient innate APCE removal
system to prevent (adaptive) immunity.
HBsAg has anti-inflammatory potential similar to APCEs
HBV is a non-cytopathogenic virus, which might explain
why HBV infections often remain unnoticed. However,
several studies have suggested a general modulation of
antigen-presenting cells [APCs; monocytes, macrophages
and dendritic cells (DCs)] in chronically infected patients.
An altered balance of Th1 and Th2 responses [5] and
defects in the antigen-presenting activity of DCs have been
observed [6]. In comparison to peripheral-blood mono-
nuclear cells (PBMCs) from healthy subjects, PBMCs from
patients with chronic HBV proliferate less frequently and
less vigorously to a non-HBV recall antigen and produce
less interferon-g (IFN-g) and interleukin-12 (IL-12)
following stimulation with mitogen [5]. In vitro studies
demonstrate a reduced capacity of PBMCs from chronic
HBV patients to produce cytokines on stimulation with
lipopolysaccharide (LPS). Interestingly, purified HBsAg,Corresponding author: Peter Vanlandschoot (Peter.Vanlandschoot@rug.ac.be).
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when added to human monocyte-derived macrophages,
efficiently suppresses the production of LPS-induced
tumour necrosis factor-a (TNF-a), vesicular stomatitis
virus-induced IFN-a and TNF-a-induced granulocyte–
macrophage-colony stimulating factor (GM-CSF). An
increased nuclear degradation of mRNA was demon-
strated [7]. Recently, yeast-expressed HBsAg (rHBsAg)
was shown to behave as an apoptotic-like particle: rHBsAg
suppressed LPS-induced secretion of proinflammatory
cytokines but increased secretion of IL-10 by monocytes
[8,9]. Similarly, binding and engulfment of APCEs sup-
presses secretion of proinflammatory cytokines and
certain chemokines by macrophages [10,11]. This effect
of APCEs is also observed when macrophages are stimu-
lated with LPS. Because addition of anti-transforming
growth factor-b (TGF-b), platelet-activating factor (PAF)
receptor anatagonist or indomethacin to APCE- and
LPS-treated macrophages restores inflammatory cytokine
production, TGF-b, PAF and prostaglandin E2 are sug-
gested to mediate the decrease of the inflammatory
cytokines [10]. Suppression is transcriptionally and trans-
lationally regulated, depending on the cytokine or chemo-
kine examined [11]. In contrast to macrophages,
monocytes do not engulf APCEs. Nevertheless, the binding
of APCEs to monocytes reduces the LPS-induced secretion
of TNF-a and IL-1b, although increased levels of IL-10 and
TGF-b can be observed [12,13]. Although IL-10 and TGF-b
are major inhibitors of TNF-a and IL-1b production, these
cytokines are not responsible for the reduction in TNF-a
and IL-1b [13]. Taken together, these observations suggest
an anti-inflammatory potential of HBsAg similar to
APCEs on monocytes and macrophages.
HBsAg interacts with molecules that bind APCEs
Several cell membrane-bound receptors have been identi-
fied that recognize APCEs: the asialoglycoprotein receptor,
class A and B scavenger receptors (SR-A and SR-BI),
CD36, macrosialin or oxidized low-density lipoprotein
(oxLDL) receptor (CD68), lectin-like oxLDL receptor-1
(LOX-1), ATP-binding cassette transporter 1 (ABC1), avb3
and avb5 vitronectin receptor, MER tyrosine kinase
receptor [a member of the TAM (Tyro–Axl–Mer tyrosine
kinase) receptor family, expressed on monocytes and
tissues of epithelial and reproductive origin], C1q receptor
(calreticulin) adhered to CD91 (a2 macroglobulin receptor,
heat-shock protein receptor or LDL receptor-related
protein), complement receptors 3 and 4 (CR3 and CR4),
the phosphatidylserine (PtdSer) receptor and CD14.
Besides these membrane receptors, several soluble factors
have been identified that bind to APCEs: thrombospondin
(TSP), C1q, C3 and C4, b2-glycoprotein I (b2-GPI),
pentraxins [PTX3, C-reactive protein (CRP) and serum
amyloid P (SAP)], growth arrest specific gene-6 product
(gas-6), mannose-binding lectin (MBL), surfactant pro-
tein-A and -D (SP-A and SP-D), histidine rich glycoprotein
(HRG), vitamin K-dependent protein S and anti-oxidized
phosphatidylcholine (anti-oxPtdCho) antibodies [14–18].
APCEs can display several molecules important for
recognition and engulfment. The most important deter-
minant for recognition of APCEs is thought to be PtdSer.
b2-GPI, gas-6, SR-A, SR-BI, CD36, CD68, ABC1, LOX-1,
CD14 and the PtdSer receptor all bind PtdSer. Several of
these also recognize other charged phospholipids (PLs),
such as phosphatidylinositol (PtdIns). Recent observations
suggest that oxPtdChos are important recognition mol-
ecules displayed by APCEs and oxidation of PtdSer
enhances engulfment of APCEs [19,20]. OxPtdCho is a
ligand for CRP, scavenger receptors and anti-oxPtdCho
antibodies. Interestingly, binding of SAP to APCEs occurs
through interaction with phosphatidylethanolamine
(PtdEtn) [21] (Fig. 1). HBsAg contains 30% (by weight)
of host-derived lipids. The main lipid components of
HBsAg are PLs (,67%), cholesteryl ester (,15%),
cholesterol (,14%) and triglycerides (,3%). PtdCho
accounts for ,90% of the PLs and PtdEtn accounts for
2–4%. Traceamounts ofPtdSer, sphingomyelin, lysoPtdCho
and lysoPtdEtn are present [22]. Because of this PL
content, HBsAg might interact with membrane-bound
receptors or soluble molecules known to bind PL that are
also displayed by APCEs. b2-GPI is a plasma protein with
high affinity for charged PLs and a key antigen in the anti-
phospholipidsyndrome [23]. Attachment of b2-GPI to
APCEs [24] depends on the presence of charged PL,
most probably PtdSer [25]. Only after binding of b2-GPI to
APCEs, a b2-GPI-dependent interaction of the complex
with macrophages becomes possible [26]. Binding of
b2-GPI to an HBsAg-containing fraction enriched for Dane
particles, was reported [27,28]. Recently, it was reported
that b2-GPI binds preferentially to Dane particles.
Experiments using recombinant HBsAg suggested that
this interaction requires binding to myristilated L protein
and depends on charged PLs, such as PtdSer. Moreover,
oxidation of the PLs is suggested to enhance binding [29].
Nevertheless, yeast and insect cell-expressed HBsAg, as
well as plasma HBsAg, have been demonstrated to bind
b2-GPI. Because of the enormous amounts of HBsAg, the
lower interaction avidity with b2-GPI might still have a
substantial anti-inflammatory effect. Another molecule
demonstrated to bind APCEs and to bind several PLs is
CD14 [30]. A soluble form of CD14 (sCD14) is present in
circulation. In chronic hepatitis B infections, levels of
sCD14 are increased but, interestingly, an inverse
correlation between HBsAg levels and sCD14 levels is
found (S. Steyaert et al., unpublished). Recently rHBsAg
was shown to behave as an apoptotic-like particle [8,9].
Additionally, rHBsAg binds to monocytes through inter-
action with the LPS-binding protein and CD14 [31].
Remarkably, plasma HBsAg does not have these charac-
teristics and the low PtdSer content (1–2%) and the lack of
PtdIns in HBsAg could cause this difference. Although
PtdIns is abundant (10–20%) in the endoplasmic reticu-
lum (ER) membrane where HBsAg particles assemble, it is
surprisingly not present in HBsAg. However, HBsAg,
when expressed in mammalian cells [such as Chinese
hamster ovary (CHO), human hepatoma cells and mouse
fibroblast cells] or yeast cells (Saccharomyces cerevisae
and Hansenula polymorpha) always contains $4–7%
of PtdSer and/or PtdIns. Considering that different
PL-transfer molecules are present in the circulation, the
question can be raised of whether or not the PL content of
HBsAg in circulation is dynamic and changes over time (or
even during storage of plasma). Soon after the discovery of
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HBsAg in circulation, the presence of HBsAg in immune
complexes containing different amounts and combinations
of IgM and/or IgG was noticed. It is often assumed that the
antibodies found in the HBsAg-immune complexes are
directed against the viral proteins of HBsAg. However, no
evidence for this has been presented. Taking into account
the high PL content of the particles, and as oxidation of
these PLs might occur during circulation, the possibility is
raised here that PL-specific or anti-oxPL antibodies are
present in the HBsAg immune complexes. Such antibodies
develop early in life, selected by the presence of oxidized
phospholipids [19]. It is thought that APCEs opsonized by
anti-oxPtdCho antibodies are removed by Fc-receptor
bearing cells. If oxidation of the PLs of HBsAg occurs
during circulation, also other molecules, such as CRP and
scavenger receptors, might perhaps interact with HBsAg.
Complement factors are also known to bind to unique
PL displayed by APCEs [32]. The circulating HBsAg
(immune) complexes can contain several complement
molecules: C1q, C1r, C1s, C4 and C3. More than 20
years ago, evidence for binding of C1q to HBsAg, possibly
in a complex with polymerized human albumin, was
presented [33]. C1q is a key molecule in the removal of
APCEs because the lack of C1q (but also C4) is associated
with decreased engulfment of APCEs and sometimes
development of disease in mice [15]. A complex interaction
between APCEs, C1q or SP-A or SP-D and calreticulin,
MBL and CD91 has been proposed [34,35]. Additionally,
the anti-inflammatory interaction of CRP with APCEs
requires C1q [36] and the circulation of apoptotic blebs in
association with C1q was demonstrated [37]. Taken
together, binding of HBsAg to (or HBsAg complexed
with) APCE-binding molecules has been demonstrated.
Depending on a (dynamic) PL content and/or oxidation of
PLs, interactions with other molecules is considered
possible.
Are circulating complement–HBsAg complexes
preventing adaptive immunity towards the viral
envelope proteins?
A recent paper described the unexpected importance of
complement and complement receptors (CR3 and CR4) in
the uptake of circulating APCEs by splenic marginal zone
DCs. Following the phagocytosis of complement-opsonized
APCEs, decreased levels of proinflammatory cytokine
secretion, without an effect on TGF-b secretion, was
observed. This cytokine switch is thought to diminish
antigen-driven T-cell stimulation by DCs that ingested
APCEs and this might lead to immune unresponsiveness
(peripheral tolerance) [38,39]. Based on these observations
it is proposed that circulating HBsAg, complexed with
complement factors (C1q, C3 and C4) might similarly be
taken up by DCs. This might lead to induction of tolerance
towards the viral envelope proteins. This mechanism could
Fig. 1. Soluble factors and cellular receptors involved in binding and phagocytosis of apoptotic cells. Those molecules that have been shown to bind to, or circulate in, com-
plexes with hepatitis B surface antigen (HBsAg) are depicted separately and are underlined. Abbreviations: ABC1, ATP-binding cassette transporter 1; anti-L, anti-L anti-
body; anti-M, anti-M antibody; anti-S, anti-S antibody; anti-oxPL, anti-oxidized phospholipid antibody; anti-oxPtdCho, anti-oxidized phosphatidylcholine antibody; b2-GPI,
b2-glycoprotein I; C1q, complement component 1q; C3, complement component 3; C4, complement component 4; CD14, lipopolysaccharide receptor; CD36, platelet
adhesion molecule; CD68, macrosialin or oxidized low-density lipoprotein (oxLDL) receptor; CD91, a2 macroglobulin receptor, heat shock protein receptor or LDL receptor-
related protein; CR3/4, complement receptor 3/4; CRP, C-reactive protein; gas-6, growth arrest specific gene-6 product; HRG, histine rich glycoprotein; LOX-1, lectin-like oxi-
dized LDL receptor-1; MBL, mannose-binding lectin; MER, MER tyrosine kinase receptor; oxPtdCho, oxidized phosphatidylcholine; oxPtdSer, oxidized phosphatidylserine;
PtdEtn, phosphatidylethanolamine; PTX3, pentraxin 3; SAP, serum amyloid P; SP-A/D, surfactant protein A/D; SR-A, class A scavenger receptor; SR-BI, BI scavenger recep-
tor; TSP, thrombospondin; Vit-K prot S, vitamin-K-dependent protein S.
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explain why an adequate anti-envelope immune response is
lacking despite the presence of HBsAg and why only after
elimination of infection, antibodies become detectable.
Concluding remarks
The evidence for the hypothesis of ‘viral apoptotic mimicry’
gathered here mainly comes from (older) studies that did
not focus on viral evasion of immunity by the HBV. It is
now hoped that this hypothesis results in renewed interest
on the possible role of HBsAg in immune evasion. Of major
importance is to determine the PL content of HBsAg, when
freshly secreted by hepatocytes, and to determine if this
content changes during circulation. If changes in PL
content or oxidation of PLs occur, the use of HBsAg
reconstituted with specific PLs might lead to the identi-
fication of serum proteins and cellular receptors known to
bind APCEs. Obviously the major APC targeted by HBsAg
needs to be identified. Finally, although future research
might reject this hypothesis for HBV, it is considered
almost inevitable that sooner or later viruses will be
identified that have targeted the APCE removal system to
avoid (adaptive) immunity.
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